Skip to main content
MedPathMedPath Home
Clinical Trials/ISRCTN66203697
ISRCTN66203697
Completed
N/A

In vivo isolation of circulating tumor cells from peripheral blood of patients with breast cancer by using a structured antibody-coated nanodetector: an explorative mono-centre non-randomised trial

GILUPI GmbH (Germany)0 sites78 target enrollmentJanuary 11, 2012
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsBreast cancer (stage I-IV)CancerMalignant neoplasm of breast

Overview

Phase
N/A
Intervention
Not specified
Conditions
Breast cancer (stage I-IV)
Sponsor
GILUPI GmbH (Germany)
Enrollment
78
Status
Completed
Last Updated
11 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
January 11, 2012
End Date
TBD
Last Updated
11 years ago
Study Type
Observational
Sex
Female

Investigators

Sponsor
GILUPI GmbH (Germany)

Eligibility Criteria

Inclusion Criteria

  • •1\. Subjects suffering from breast cancer (diagnosed), they are qualified for radical operation of the tumor
  • •2\. Age \= 18 years
  • •3\. Results of laboratory tests are in the area that the patient is qualified to perform an operation
  • •4\. Written informed consent

Exclusion Criteria

  • •1\. All results of laboratory tests which represent in the opinion of the auditor a risk to the participation of the patient
  • •2\. Different types of allergies (including hay fever)
  • •3\. Anaphylactic or anaphylactoid reactions
  • •4\. Each of the following autoimmune diseases: antiphospholipid syndrome (lupus anticoagulant), goodpasture's syndrome, lupus erythematosus, recurrent polychondritis, rheumatoid arthritis, sarcoidosis, scleroderma, Sjogren's syndrome, anti\-neutrophil cytoplasmic antibodies (ANCA)
  • •5\. All forms of immune deficiency: X\-linked agammaglobulinemia (XLA), severe combined
  • •immunodeficiency (SCID), common variable immunodeficiency (CVID), the lack of immunoglobulin A
  • •6\. Serological diagnosis: hepatitis A, B and C, human immunodeficiency virus (HIV), herpes simplex virus (HSV), cytomegalovirus (CMV), syphilis (Wassermann positive test), toxoplasmosis, tuberculosis
  • •7\. Laboratory abnormalities of patients with a negative performance for the surgery
  • •8\. Detectable inflammatory responses

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
N/A
In vivo isolation of circulating tumor cells from peripheral blood of patients with lung cancer by using a structured antibody-coated nanodetectorung cancer (non small cell lung cancer - NSCLC, stage I-IV)CancerMalignanat neoplasm of bronchus or lung, unspecified
ISRCTN55277999GILUPI GmbH (Germany)60
Completed
N/A
Isolation of circulating tumor cells from the blood of prostate cancer patients using an antibody-coated nanodetectorProstate cancer (all stages), Benign prostatic hyperplasia (all stages)CancerMalignant neoplasm of prostate
ISRCTN10403616GILUPI GmbH (Germany)105
Completed
N/A
Sorting of circulating tumor cells from patients with gastric cancer and genomic DNA extraction: a prospective feasibility studyGastric cancer
JPRN-UMIN000008924Digestive Disease Center, Showa University Northern Yokohama Hospital20
Completed
N/A
Sorting of circulating tumor cells from patients with esophageal cancer and genomic DNA extraction: a prospective feasibility studyEsophageal cancer
JPRN-UMIN000008925Digestive Disease Center, Showa University Northern Yokohama Hospital20
Completed
N/A
Sorting of circulating tumor cells from patients with gastrointestinal stromal tumor and genomic DNA extraction: a prospective feasibility studyGastrointestinal stromal tumor
JPRN-UMIN000008930Digestive Disease Center, Showa University Northern Yokohama Hospital20